Concepedia

Jinlong Xu

JX

Statistics

Publications

13

Citations

751

H-Index

11

Active since

2020

Affiliations

Institute of Hematology & Blood Diseases Hospital(Current)

Chinese Academy of Medical Sciences & Peking Union Medical College

Beijing Tongren Hospital

Fujian Medical University

Union Hospital

Jinlong Xu is an author at Institute of Hematology & Blood Diseases Hospital specializing in immunotherapy, cytotoxic t lymphocyte responses, and life sciences.

ORCID

Publications per year

2020–2025

13

Publications

13

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Jing Pan, Yue Tan, Guoling Wang et al. · Journal of Clinical Oncology · 2021 · 294 citations

, , +15

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy

Jing Pan, Biping Deng, Zhuojun Ling et al. · Journal of Cellular and Molecular Medicine · 2020 · 91 citations · Full text

, , +17

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

Yue Tan, Lingling Shan, Liping Zhao et al. · Journal of Hematology & Oncology · 2023 · 84 citations · Full text

, , +17

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study

Jing Pan, Kaiting Tang, Yuechen Luo et al. · The Lancet Oncology · 2023 · 65 citations

, , +16

Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

Jing Pan, Yue Tan, Lingling Shan et al. · Nature Medicine · 2024 · 45 citations

, , +15

1–5 of 13